CT-assessed sarcopenia combined with inflammatory markers predicts higher mortality in critically ill and COVID-19 patientsLow muscle mass and inflammation linked to higher COVID-19 mortality

This meta-analysis evaluated the prognostic utility of CT-assessed sarcopenia combined with laboratory inflammatory markers (CRP, IL-6, NLR) in patients with COVID-19 and other critical conditions. The study included a total sample size of 12,347 patients, including critically ill, pulmonary, and geriatric populations. The primary objective was to determine if combining muscle mass measurements with inflammatory indicators provided superior predictive value for mortality compared to individual measures (CT-sarcopenia alone or inflammatory markers alone) and established clinical scoring systems such as APACHE II, SOFA, CURB-65, and PSI.

The analysis focused on the interaction between skeletal muscle mass and systemic inflammation. Specifically, it examined how CT-derived measurements of muscle mass correlated with biomarkers including C-reactive protein (CRP), fibrinogen, D-dimers, and white blood cell (WBC) counts. The study also assessed secondary outcomes, including the duration of mechanical ventilation and length of stay in the intensive care unit (ICU).

Regarding primary outcomes, the meta-analysis revealed significant associations between sarcopenia and mortality. In critically ill ICU cohorts, patients identified as sarcopenic showed an increased odds of mortality with an OR of 2.28 (95% CI: 1.83-2.83; I2 = 22.1%). For COVID-19 pulmonary populations specifically characterized by low skeletal muscle mass, the risk was even more pronounced, showing an increased odds of mortality with an OR of 5.84 (95% CI: 1.07-31.83). These findings indicate that sarcopenia is a potent independent predictor in these patient groups.

Correlation analyses showed significant inverse relationships between CT-derived muscle measurements and several inflammatory markers. Specifically, the results showed r = -0.315 for CRP, r = -0.392 for fibrinogen, r = -0.363 for D-dimers, and r = -0.287 for WBC count. These negative correlations suggest that lower muscle mass is associated with higher levels of systemic inflammation.

In terms of prognostic accuracy, the combined model of CT-sarcopenia and inflammatory markers outperformed conventional scoring systems including APACHE II, SOFA, CURB-65, and PSI. While the specific effect sizes for these comparisons were not reported, the qualitative finding indicates that a multimodal approach provides superior predictive value over traditional single-metric or standard clinical scores.

Safety and tolerability data were not reported as the study utilized observational data to establish prognostic associations rather than testing an intervention. The results should be interpreted with caution as they are based on a meta-analysis of observational studies, meaning they indicate association rather than causation. Furthermore, while the combined model showed superior performance over standard scores, specific quantitative metrics for that comparison were not provided.

Clinically, these findings suggest that integrating CT-assessed sarcopenia with inflammatory markers provides a robust multimodal prognostic framework for critically ill, pulmonary, and geriatric patients. This approach may allow for more nuanced risk stratification than traditional scoring systems alone. However, the integration of these metrics into routine clinical practice requires further validation in prospective settings to determine if this improved prediction translates into improved patient outcomes.